Drugs / IMCnyeso
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03515551 | Jun 2018 → May 2021 | neoplasm | Immunocore Ltd | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMCnyeso | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03515551 ↗ |
| Modality | Protein / enzyme biologic | “bispecific fusion protein” NCT03515551 ↗ |
| Route | Intravenous | “Weekly IV infusions of IMCnyeso” NCT03515551 ↗ |